- Home
- RYN vs ACLX Comparison
RYN vs ACLX Comparison
Compare RYN & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$22.03
HOLD
Current Price
$67.75
Company Overview
Basic Information| Metric | RYN | ACLX |
|---|---|---|
| Founded | 1926 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 4.2B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | RYN | ACLX |
|---|---|---|
| Price | $22.03 | $67.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $27.25 | ★ $115.71 |
| AVG Volume (30 Days) | 1.4M | ★ 1.4M |
| Earning Date | 02-04-2026 | 11-05-2025 |
| Dividend Yield | ★ 13.23% | N/A |
| EPS Growth | ★ 373.89 | N/A |
| EPS | ★ 5.07 | N/A |
| Revenue | ★ $1,293,371,000.00 | $35,898,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $302.49 |
| P/E Ratio | $4.31 | ★ N/A |
| Revenue Growth | ★ 60.70 | N/A |
| 52 Week Low | $21.06 | $47.86 |
| 52 Week High | $29.38 | $94.07 |
Technical Indicators
Market Signals| Indicator | RYN | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 35.94 |
| Support Level | $21.59 | $68.64 |
| Resistance Level | $22.85 | $73.98 |
| Average True Range (ATR) | 0.53 | 4.69 |
| MACD | 0.15 | -0.20 |
| Stochastic Oscillator | 50.75 | 18.18 |
Price Performance
Historical Comparison RYN
ACLX
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.